Immune Cytolysis of Human Renal Carcinoma Mediated by Xenogeneic Immune Ribonucleic Acid

Brower, Paul; deKernion, Jean B.; Ramming, Kenneth P.

doi:10.1016/s0022-5347(17)59156-9

Cited by 14 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune cytolysis of human renal, bladder, and lung carcinoma cells in vitro by xenogeneic I-RNA has also been reported by Browers et al [20]. No autologous systems were included in these studies.…”

Section: Mediation Of Immune Responses To Human Tumor Ceils In Vitrosupporting

confidence: 56%

“…Although treatment of lymphocytes in vitro with I-RNA has been shown to induce such lymphocytes to affect antitumor immune responses in vivo and in vitro [16][17][18][19][20]24], we have as yet treated only 2 patients by the intravenous infusion of autologous lymphocytes preincubated in vitro with I-RNA. Our initial reluctance to utilize this approach was due to the fear of inducing untoward allergic reactions related to small amounts of sheep protein which contaminate the I-RNA and might be expected to remain with the lymphocytes even after several washes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy of human malignancies with immune RNA

1977

View full text Add to dashboard Cite

Immune RNA (I-RNA) is an RNA-rich nucleic acid preparation extracted from lymphoid cells or tissues following exposure to specific antigens in vitro or sensitization to specific antigens in vivo. It has been shown to induce normal, nonimmune lymphoid cells to mediate specific cellular and humoral immune responses in vitro and in vivo. Previous studies have demonstrated that I-RNA preparations extracted from the lymphoid organs of animals immunized with tumor cells mediate specific immune responses against tumor associated antigens in both animal models and human tumor systems. Based on this work, prelimiqary clinical trials of I-RNA immunotherapy were initiated 3 years ago. Cancer patients were treated with I-RNA extracted from the lymphoid organs of sheep immunized with either autologous tumor cells or allogeneic tumor cells of the same histoiogir type. I-RNA was administered weekly, intradermalhy, at doses of 4 to 8 mg/week without any significant local or systemic toxicity. The results of these preliminary rtrials suggest increased survival in patients with metastatic hypernephroma and possible benefit in the form of decreased recurrence rate in the adjuvant immunotherapy of patients with malignant melanoma. A prospectively randomized trial of adjuvant immunotberapy with I-RNA in patients with Dukes' classes B2 and C colorectal cancer has been recent!y undertaken. Animal ExperimentsThe initial interest in immune RNA (I-RNA) was stimulated by the observation, in the early 1960's. that RNA extracted from lymphoid cells which had Supported in part by grants number CA-21664. CA-12582. CA-16402. and NIH-4-444992-32691 from the National Institutes of Health and by grant number 1797-03 from the Veterans Administration.

show abstract

Section: Mediation Of Immune Responses To Human Tumor Ceils In Vitrosupporting

confidence: 56%

Section: Discussionmentioning

confidence: 99%

Immunotherapy of human malignancies with immune RNA

1977

View full text Add to dashboard Cite

show abstract

“…An adult sheep was immunized against B16 melanoma by modification of the procedure of Brower et al [34]. Two to three grams of B16 melanoma were minced and suspended in 4 ml of normal saline.…”

Section: Preparation Of Xenogeneic Immune Rnamentioning

confidence: 99%

Immune RNA Therapy as an Effective Adjuvant Immunotherapy After Surgery: An Animal Model

et al. 1983

View full text Add to dashboard Cite

~ Transfer of tumor immunity as adjuvant cancer therapy has been a topic of intense interest. We have examined the efficacy of various combinations of surgery, xenogeneic immune RNA, xenogeneic normal RNA, tumor vaccine, and nonspecific splenocytes as adjuvant therapy for B16 melanoma in the C57BL/6J mouse system. B16 melanoma was transplanted by trocar into the right hind limb of 6-week-old mice. The tumors were readily palpable on the ninth day posttransplantation. The tumors were amputated at that time under mild anesthesia. Immune RNA was prepared by hot phenol extraction from immune sheep spleens. Various combinations of immune RNA, normal RNA, and tumor antigen, with or without normal mouse spleen cells, were administered every other day for a total of 10 injections. The survival and mode of death was followed up to 120 days. All mice without any treatment died within 30 days. Immunotherapy had no effect on the survival of mice that did not have surgical therapy. Individual group comparisons between mice that underwent surgery only and mice that had surgery plus immune RNA immunotherapy revealed a striking statistical improvement (P < 0.01). Comparing all groups that received amputation plus various combinations of adjuvant immunotherapy showed no statistical difference in survival. However, immune RNA appears somewhat superior to normal RNA or antigen only. It appears that adjuvant immune RNA immunotherapy following surgical excision in the B 16 melanoma model significantly improves survival and retards the spread of metastases.

show abstract

Immune RNA therapy as an effective adjuvant immunotherapy after surgery: An animal model

Aarons

Krishnan

Mebust

et al. 1983

Journal of Surgical Oncology

View full text Add to dashboard Cite

Transfer of tumor immunity as adjuvant cancer therapy has been a topic of intense interest. We have examined the efficacy of various combinations of surgery, xenogeneic immune RNA, xenogeneic normal RNA, tumor vaccine, and nonspecific splenocytes as adjuvant therapy for B16 melanoma in the C57BL/6J mouse system. B16 melanoma was transplanted by trocar into the right hind limb of 6-week-old mice. The tumors were readily palpable on the ninth day posttransplantation. The tumors were amputated at that time under mild anesthesia. Immune RNA was prepared by hot phenol extraction from immune sheep spleens. Various combinations of immune RNA, normal RNA, and tumor antigen, with or without normal mouse spleen cells, were administered every other day for a total of 10 injections. The survival and mode of death was followed up to 120 days. All mice without any treatment died within 30 days. Immunotherapy had no effect on the survival of mice that did not have surgical therapy. Individual group comparisons between mice that underwent surgery only and mice that had surgery plus immune RNA immunotherapy revealed a striking statistical improvement (P less than 0.01). Comparing all groups that received amputation plus various combinations of adjuvant immunotherapy showed no statistical difference in survival. However, immune RNA appears somewhat superior to normal RNA or antigen only. It appears that adjuvant immune RNA immunotherapy following surgical excision in the B16 melanoma model significantly improves survival and retards the spread of metastases.

show abstract

Immune Cytolysis of Human Renal Carcinoma Mediated by Xenogeneic Immune Ribonucleic Acid

Cited by 14 publications

References 7 publications

Immunotherapy of human malignancies with immune RNA

Immunotherapy of human malignancies with immune RNA

Immune RNA Therapy as an Effective Adjuvant Immunotherapy After Surgery: An Animal Model

Immune RNA therapy as an effective adjuvant immunotherapy after surgery: An animal model

Contact Info

Product

Resources

About